Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Spin it baby. Huge volume and price decline, although it's a good thing. Lol
I love hearing about a "buy out". Every penny stock has the dream of being bought out.
The last time I saw the stock move from a PR was about two years ago. It was when they release the first channel partners name and then they tried it again a couple months later but it didn't work. With all these huge trades I think sub Penny days are coming soon
Yawn - come on Kate give us an update!
I wonder how PP is liking his .023's he bought a couple weeks ago??
I think they are trying to keep up the price, but the selling is too much.
wow .0165 - BLOOD BATH
WOW - 460K on the bid @ .0181 - I've never seen it this bad! This could be sub penny this week.
Dam those evil market makers and shorts trying to destroy VLDI - no way it was investors dumping shares, bc no one is selling, right? :)
Biotech Firm Sees Option For Home Addiction Treatment Similar To Giving Insulin For Diabetes
Brady Granier, the CEO of California-based BioCorRx, says that he hopes to develop a low-dose, injectable-form of naltrexone that uses a small needle so that people could administer it at home.
Stat: Company Hopes To Make Addiction Treatment For Home Use
A California-based addiction treatment company hopes to change the way patients struggling with substance abuse disorder receive a popular form of medication-assisted treatment. If approved, patients could self-administer naltrexone, an opioid antagonist, in the comfort of their own homes — like insulin, but for recovering addicts. The promise of this advancement has some addiction experts excited about a product that could reduce the stigma surrounding recovery. Others, though, remain wary of moving such treatment out of a doctor’s office and away from wraparound services seen as essential for staying clean. (Blau, 4/28)
http://californiahealthline.org/morning-breakout/biotech-firm-sees-option-for-home-addiction-treatment-similar-to-giving-insulin-for-diabetes/
SEC is cracking down
Lol - don't think otc stocks can be halted for news. Maybe it for suspended ha
I bet we will get some institutional investors pouring in next week.
Thanks for the insight. I was told all this 4 years ago and nothing has happened to increase the value of my investment. How much longer do I have to wait? What do you suggest? Just keep waiting and buy more?
We discuss facts about VLDI and speculation. VLDI is way overdue to deliver so all the "what ifs" don't get much love here.
so you think VLDI is worth 10 billion dollars?
Actually if you were invested in the big boards last few years you would've made a killing. Unfortunately, everybody in VLDI probably lost at least 70 - 80% of their money. That doesn't sound like a very good strategy to me.
Just what I thought - over 33% increase in sales. BICX has a superior product to battle the opioid epidemic. BICX101 has to be on ALKS radar big time. Huge buyout potential here.
Net sales of VIVITROL were $58.5 million, compared to $43.8 million for the same period in the prior year, representing an increase of approximately 33.4%.
ALKS earnings today. I bet they hit a home run again with VIVITROL
NWBO .25+ today!
Penny stock investing might not be the best idea for you. Although, it is Penny land so I guess anything is possible.
Lol - we both know that is impossible.
A messaging app sounded like a good a idea a few years ago, but it's way too late now. Another example of a recycled useless PR.
Stock is trading below .02 so why don't you explain that? I forgot, it's another buying opportunity like the last 500 of them.
So they already had an IOU for 400,000 from years ago? Then they gave them another IOU for 400,000 and tore up the original one? Am getting that correct? Like I said, no money changed hands.
Normally I would be buying at these levels but I think the time has come when this is not going to recover. The weight of all those convertibles is much too heavy.
Ganthet didn't actually pay anything. They gave VLDI an IOU....
any idea what the shares outstanding are fully diluted with the warrants?
I think it's safe to say most investors here don't understand software development/technology or how to read filings.
Below is about $400K in the next few months. If they convert at .01 it's about 40 million shares that can be sold for whatever the bid is.
$30,000 of the notes issued during the year ended December 31, 2016 had a maturity date of May 9, 2017, and could be prepaid during the period from issuance to November 5, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which is unpaid at November 5, 2016, or thereafter, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.
$262,500 of the notes issued during the year ended December 31, 2016 mature on August 24, 2017, and may be prepaid during the period from issuance to February 24, 2017, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at February 24, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as 55% of the lowest closing bid price of the common stock during the ten prior trading days including the day upon which the conversion request is executed.
$100,000 of the notes issued during the year ended December 31, 2016 mature on May 31, 2017, and may be prepaid during the period from issuance to February 27, 2017, in full, at various rates ranging from 140% to 150% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at February 27, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.
These note holders will pretty much double their money no matter what the stock is trading at. the bid is below .02 right now so they can convert at subpenny - 100's of millions of shares will be available for dumpage starting in May.
From the 10K:
Convertible promissory notes:
During the year ended December 31, 2016, the Corporation issued $973,611 of its convertible promissory notes for cash. The notes bear interest at the rate of 8% until they mature, or until there is an event of default; thereafter, any portion of the principal or interest which has not been settled will be subject to interest at the rate of 22% per annum.
$55,000 of the notes issued during the year ended December 31, 2016 had a maturity date of on January 5, 2017, and could be prepaid during the period from issuance to July 3, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which is unpaid at July 3, 2016, or thereafter, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 40%.
$50,000 of the notes issued during the year ended December 31, 2016 had a maturity date of November 8, 2016, and could be prepaid during the period from issuance to July 29, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which was unpaid at July 29, 2016 or thereafter, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest three trading prices during the ten trading days immediately preceding such conversion, discounted by 49%.
$40,000 of the notes issued during the year ended December 31, 2016 had a maturity date of February 22, 2017, and could be prepaid during the period from issuance to August 20, 2016, in part or in full, at various rates ranging from 120% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which is unpaid at any time, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.
$111,111 of the notes issued during the year ended December 31, 2016 had a maturity date of March 2, 2018. The holder had the option to convert any balance of principal and interest which was unpaid at August 29, 2016 or thereafter, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest two trading prices during the twenty-five trading days immediately preceding such conversion, discounted by 40%.
$100,000 of the notes issued during the year ended December 31, 2016 had a maturity date of December 15, 2016, and could be prepaid during the period from issuance to September 11, 2016, in full, at various rates ranging from 135% to 150% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which was unpaid at September 11, 2016 or thereafter, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.
$30,000 of the notes issued during the year ended December 31, 2016 had a maturity date of May 9, 2017, and could be prepaid during the period from issuance to November 5, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which is unpaid at November 5, 2016, or thereafter, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.
$262,500 of the notes issued during the year ended December 31, 2016 mature on August 24, 2017, and may be prepaid during the period from issuance to February 24, 2017, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at February 24, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as 55% of the lowest closing bid price of the common stock during the ten prior trading days including the day upon which the conversion request is executed.
$100,000 of the notes issued during the year ended December 31, 2016 mature on May 31, 2017, and may be prepaid during the period from issuance to February 27, 2017, in full, at various rates ranging from 140% to 150% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at February 27, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.
$60,000 of the notes issued during the year ended December 31, 2016 mature on November 30, 2017, and may be prepaid during the period from issuance to May 28, 2017, in part or in full, at various rates ranging from 120% to 150% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at May 28, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.
$165,000 of the notes issued during the year ended December 31, 2016 , and may be prepaid during the period from issuance to May 26, 2017, in full, at various rates ranging from 120% to 150% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at May 26, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 40%.
$858,278, representing the relative fair value of the beneficial conversion feature of the notes at date of issuance, was allocated to additional paid in capital; the notes are being accreted to their face value over the term of the notes, through periodic charges to interest expense using the effective interest rate method.
$22,250 in finance fees were incurred in relation to the convertible promissory notes issued during 2016, and are being charged to interest and financing costs over the term of the notes, using the effective interest rate method.
$57,611 in original issue discounts were incurred in relation to the convertible promissory notes issued during 2016, and are being charged to interest and financing costs over the term of the notes, using the effective interest rate method.
During the year ended December 31, 2016, holders of the convertible promissory notes exercised the conversion feature of the notes, and converted $315,500 of note principal, and $13,142.32 of accrued interest on the notes, into 23,962,703 common shares of the Corporation.
Also during the year ended December 31, 2016, the Corporation exercised the prepayment option and issued aggregate cash payments of $477,335 in settlement of $316,111 in principal amount, plus accrued interest and prepayment bonus thereon of $161,224.
During the year ended December 31, 2015, the Corporation issued $449,000 of its convertible promissory notes for cash.
$53,500 of the notes issued during the year ended December 31, 2015 had a maturity date of October 12, 2015, and could be prepaid during the period from issuance to July 7, 2015, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which was unpaid at July 7, 2015 or thereafter, into common stock of the Company.
$53,500 of the notes issued during the year ended December 31, 2015 had a maturity date of December 4, 2015, and could be prepaid during the period from issuance to August 28, 2015, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which was unpaid at August 28, 2015, or thereafter, into common stock of the Company. .
4
$53,500 of the notes issued during the year ended December 31, 2015 matured on December 31, 2015 and could be prepaid during the period from issuance to September 23, 2015, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which is unpaid at September 23, 2015, or thereafter, into common stock of the Company.
$43,000 of the notes issued during the year ended December 31, 2015 matured on March 9, 2016, and could be prepaid during the period from issuance to November 30, 2015, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which is unpaid at November 30, 2015, or thereafter, into common stock of the Company.
$64,000 of the notes issued during the year ended December 31, 2015 mature on April 27, 2016, and could be prepaid during the period from issuance to January 19, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which was unpaid at January 19, 2016, or thereafter, into common stock of the Company.
$54,000 of the notes of the notes issued during the year ended December 31, 2015 mature on Jun 4, 2016 and could be prepaid during the period from issuance to February 28, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which was unpaid at February 28, 2016, or thereafter, into common stock of the Company.
$54,000 of the notes issued during the year ended December 31, 2015 mature on July 23, 2016 and may be prepaid during the period from issuance to April 19, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at April 19, 2016, or thereafter, into common stock of the Company.
$73,500 of the notes issued during the year ended December 31, 2015 mature on November 20, 2017 and may be prepaid during the period from issuance to April 18, 2016, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert all or any amount of the outstanding principal face amount of the note, plus accrued interest thereon, into common stock of the Company.
The rate of conversion for $375,500 of the notes issued by the Corporation during the year ended December 31, 2015 is the average of the lowest three trading prices during the ten trading days immediately preceding such conversion, discounted by 49%; the rate of conversion for $73,500 of the notes issued by the Corporation during the year ended December 31, 2015 is the average of the lowest three trading prices during the ten trading days immediately preceding such conversion, discounted by 45%.
$430,436, representing the relative fair value of the beneficial conversion feature of the notes at date of issuance, was allocated to additional paid in capital; the notes are being accreted to their face value over the term of the notes, through periodic charges to interest expense using the effective interest rate method.
$29,000 in finance fees were incurred in relation to the convertible promissory notes issued during 2015, and are being charged to interest and financing costs over the term of the notes, using the effective interest rate method.
$3,500 in original issue discounts were incurred in relation to the convertible promissory notes issued during 2015, and are being charged to interest and financing costs over the term of the notes, using the effective interest rate method.
During the year ended December 31, 2015, holders of the convertible promissory notes exercised the conversion feature of the notes, and converted $187,500 of note principal, and $7,495 of accrued interest on the notes, into 11,399,708 common shares of the Corporation.
Also during the year ended December 31, 2015, the Corporation exercised the prepayment option and issued aggregate cash payments of $358,827 in settlement of $241,000 in principal amount, plus accrued interest and prepayment bonus thereon of $117,827.
The discount to market conversion feature of the convertible promissory notes causes a theoretical possibility that the Corporation may be required to settle the notes by issuing more shares than are authorized. Furthermore, this feature causes the notes to fall within the FAS 133 definition of a derivative liability. Management has calculated that the maximum number of shares required to convert the principal plus accrued interest on the convertible notes at December 31, 2016 was 34,618,076, which represents approximately 13% of the authorized, unissued shares at that date, and has also estimated that the fair value of the notes at December 31, 2016 approximates face value, therefore no adjustment for fair value restatement has been made.
At December 31, 2016, the fair value of the stock issuable to fully convert the convertible promissory note principal was $1,019,678, which exceeds the principal amount by $432,178.
Just keep buying! Don't worry about selling ever
$1+ or subpenny. Place your bets!
I feel a PR coming and insiders are loading up.
I think that huge trade yesterday was a sign of what is to come. Word is getting out about BICX.
Very confident for someone to drop that amount of money. I bet the investor is banking to double his money at the very least.
time to load up!
I have my bid in for these cheapies, but it won't fill! This is ready to goto the moooon! I guess I better hit the offer before it's too late...
yes, the clock keeps getting reset and nothing ever progresses. I am sure a reverse split will be resetting the share count soon as well....
Tons of investors on the sidelines waiting for positive FDA news to jump in. Innovative Science Solutions are experts at navigating the FDA approval pathways so it's only a matter of time.